Adalimumab – Humira

CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Phase
Study Indication or Disease
Study Name
W12-122 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 Radiographic, Clinical and Patient outcomes in a multicenter, open-label phase IV randomized trial of earlier Adalimumab introduction therapy versus later introduction as per standard of care after initial Methotrexate failure in Early Rheumatoid Arthritis patients (RADAR)
HUM 05-3 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis Phase 4 A long term documentation to demonstrate long term efficacy and safety of Humira® in patients with psoriatic arthritis under conditions of daily practice
W11-050 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 4 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
W10-151 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)
W10-046 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)
M12-073 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy with Adalimumab in Subjects with Early Rheumatoid Arthritis (CONCERTO)
P10-733 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis
PMOS-CANA-04-01 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
M13-687 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics after Dose Escalation in Japanese Subjects with Crohn's Disease
M11-991 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis Phase 3 A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
P13-708 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population
HUM 03-1 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
M13-279 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 4 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
M10-880 AbbVie_IU_icons_outlined_v3 Uveitis Phase 3 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis – Including a Sub-study in Japanese Patients
W06-405 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects with Moderate to Severe Crohn’s Disease (ACCESS)
W06-406 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients with Active Rheumatoid Arthritis
P12-261 AbbVie_IU_icons_outlined_v3 Psoriasis PMOS Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
P10-448 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
M02-497 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 An open-label, multi-center study to assess the safety and efficacy of the fully human anti-TNF monoclonal antibody Adalimumab (D2E7) when added to inadequate standard anti-rheumatic therapy in patients with active rheumatoid arthritis
P13-983 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Assessment of the safety of adalimumab in rheumatoid arthritis (RA) patients showing rapid progression of structural damage of the joints, who have no prior history of treatment with disease-modifying antirheumatic drugs (DMARDs) or biological agents
P10-559 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Humira 40mg/0.8ml for Subcutaneous Injection-Drug Use Investigation (All Patient Investigation) for Rheumatoid Arthritis
M12-088 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 A Multicenter, Randomized, Open-Label Study of the Injection Time and Usability of the Physiolis Syringe and Autoinjector in Injection-Experienced Rheumatoid Arthritis Patients
P12-768 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis PMOS Multicountry Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
MEXI-P01-03 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR. Abbott Laboratories (Abbott) will use reasonable…
W10-045 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 Open-Label, Multi-country and Multi-Center Study to Assess the Clinical Efficacy and impact on QoL of the Fully Human Anti-TNF-alfa Monoclonal Antibody Adalimumab (Humira) when Added to Inadequate Standard Anti-Rheumatic Therapy in patients with Active Rheumatoid Arthritis in a period of 6 months treatment
P12-070 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Special Investigation (Long-term Treatment in Patients With Rheumatoid Arthritis)
P12-265 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS An Observational Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
P12-129 AbbVie_IU_icons_outlined_v3 Psoriasis PMOS Evaluation of Humira Retention Rate in Psoriasis in Daily Practice and Assessment of Work Productivity and Quality of Life
DE038 AbbVie_IU_icons_outlined_v3 Juvenile Idiopathic Arthritis Phase 3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children
M11-964 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis
M02-404 AbbVie_IU_icons_outlined_v3 Crohn's Disease CSR.ORG A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the I…
M02-433 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects with Crohn's Disease
M10-877 AbbVie_IU_icons_outlined_v3 Uveitis Phase 3 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis – Including a Sub-study in Japanese Patients
M13-390 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 Study to Assess the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of a New Adalimumab Formulation in Subjects With Active Rheumatoid Arthritis
P13-974 AbbVie_IU_icons_outlined_v3 Crohn's Disease PMOS An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a Korean Experience
P12-069 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859))
M14-232 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 2 A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects with Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein
P10-147 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis PMOS Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice
P12-165 AbbVie_IU_icons_outlined_v3 Psoriasis PMOS Effectiveness of Adalimumab (Humira) in the Treatment of Scalp and Nail Affection in Patients with Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
M12-783 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis.
P12-770 AbbVie_IU_icons_outlined_v3 Psoriasis PMOS Effectiveness of Adalimumab in moderate to severe Plaque Psoriasis Patients with distinct Co-morbidities
P11-067 AbbVie_IU_icons_outlined_v3 Psoriasis PMOS Post-Authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA®) on Moderate-Severe Psoriasis under Conditions of Normal Clinical Practice in Spain
P13-683 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Physical Activity in Patients with Rheumatoid Arthritis Treated with Adalimumab in Routine Clinical Practice
M12-071 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 A Multicenter, Double-Blind, Randomized, Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis Treated With Adalimumab (MUSICA)
P12-772 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS The documentation of the effects on Quality of Life (QOL) and Working Productivity and Activity Impairment (WPAI) in patients with rheumatoid arthritis (RA) under HUMIRA® (Adalimumab) in routine clinical practice.
P13-338 AbbVie_IU_icons_outlined_v3 Crohn's Disease PMOS IDEA Study: Improvement of Work Productivity and Quality of Life with anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey
DE018 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multi-Centre Open Label Continuation Study with Subcutaneous D2E7 (adalimumab) for Patients with Rheumatoid Arthritis Who Completed a Preceding Clinical Study with D2E7 (adalimumab)
P12-707 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS An extended observational study (P12-707: HOPEFUL III Study) of follow-up survey (P12-069: HOPEFUL II study) of the study of adalimumab (D2E7) for prevention of joint destruction in patients with rheumatoid arthritis in Japan (M06-859)
P12-179 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS A 2-year HRQL Observational Study Evaluating the Effect of Treatment with Adalimumab on Work Productivity and Sleep in Patients with Rheumatic Diseases in Greece.
P12-706 AbbVie_IU_icons_outlined_v3 Crohn's Disease PMOS Special Investigation (All cases investigation in patients with Crohn's Disease)
P12-072 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS A Post-Marketing Observational Study to Determine the Effectiveness and Patient Satisfaction with Adalimumab (Humira®) Treatment in Patients with Rheumatoid Arthritis (RA) (PASSION)
P13-682 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Impact of Adalimumab Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients with Ankylosing Spondylitis in Clinical Practice
M11-328 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis Phase 3 A Double-Blind, Placebo -Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis
DE020 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis
W05-399 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis Phase 3 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
W06-407 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)
P12-627 AbbVie_IU_icons_outlined_v3 Psoriasis PMOS A Real World Observational Study to Evaluate the Impact of Adalimumab Therapy on Quality of Life and Psychological Factors Associated With Severe Psoriasis
DE013 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Prospective Multi-Center Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week with Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate (MTX) Administered over 2 Years in Patients with Early Rheumatoid Arthritis (PREMIER)
P06-134 AbbVie_IU_icons_outlined_v3 Crohn's Disease PMOS A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Subjects with Moderately to Severely Active Crohn's Disease (CD)
M04-717 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 A Multicenter, Randomized, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Pediatric Subjects with Chronic Plaque Psoriasis (Ps)
M10-883 AbbVie_IU_icons_outlined_v3 Spondyloarthritis Phase 3 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis
M11-313 AbbVie_IU_icons_outlined_v3 Hidradenitis Suppurativa (HS) Phase 3 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I
P10-604 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use
P12-585 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis patients who are about to be treated with Adalimumab
P10-278 AbbVie_IU_icons_outlined_v3 Crohn's Disease PMOS Post-marketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA (Adalimumab SC) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice.
DE019 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate
M13-045 AbbVie_IU_icons_outlined_v3 Ulcerative Colitis Phase 3 An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
M13-674 AbbVie_IU_icons_outlined_v3 Nail Psoriasis Phase 3 A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis.
P14-362 AbbVie_IU_icons_outlined_v3 Juvenile Idiopathic Arthritis PMOS Post-Marketing Surveillance of Humira® Injection in Korean JIA Patients under the New-Drug Re-examination
P13-194 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis in China
M11-810 AbbVie_IU_icons_outlined_v3 Hidradenitis Suppurativa (HS) Phase 3 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II
P12-598 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis PMOS The Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER)
M11-509 AbbVie_IU_icons_outlined_v3 Intestinal Behcet's Phase 3 A Multi-Center Study of Adalimumab in Japanese Subjects with Intestinal Behçet's Disease
M02-574 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody (D2E7) in Patients with Active Rheumatiod Arthritis
M02-527 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 A mulit-centre randomised, double-blind study comparing adalimumab (D2E7) plus methotrexate with placebo plus methotrexate on work disability in subjects with early rheumatoid arthritis
M03-651 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 Open-Label Continuous Administration Study with Adalimumab (D2E7) in Subjects with Rheumatoid Arthritis
M04-702 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 2 A Multicenter Open-Label Continuation Study of the Long-term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
M13-606 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira®) in Chinese Subjects with Moderate to Severe Plaque Psoriasis
W05-399 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis CSR.ORG A Canadian Open-label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Tre...
M03-596 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG Phase 2 Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis A…
M03-656 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG A Phase 3, Multicenter Study of the Efficacy and Safety of Long-term Adalimumab Treatment in Subjects with Moderate to Severe C…
MEXI-P01-03 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 Quality of Life Study with Adalimumab in Rheumatoid Arthritis D2E7, adalimumab, HUMIRA, Phase 3, Phase III, Rheumatoid Arthritis, RA
M02-527 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Multi-centre Randomised, Double-blind Study Comparing Adalimumab (D2E7) Plus MTX With Placebo Plus MTX on Work Disability in S…
M04-688 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Adalimumab (D2E7) in Jap...
M02-573 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Randomized, Double-Blind, Placebo-Controlled, Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Inj...
M04-691 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab
M02-570 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis CSR.ORG A Phase III Multicenter Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Moderate to…
M05-769 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects with Crohn's Disease Involving the Colon
M06-829 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease
M02-498 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects with Active Rheumatoid Arthritis Abb...
M04-716 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of A…
M02-538 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG Phase 2 Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Abbott Labo…
M02-574 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Multicenter Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients with Active…
M06-808 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab
M10-261 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multi-center, Randomized, Double-blind, Placebo-controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared with 40 mg Adalimumab Every Other Week Dosing
M04-688 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 2 A Phase 2/3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Adalimumab (D2E7) in Japanese Subjects with Moderate to Severe Chronic Plaque Psoriasis
M02-537 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis CSR.ORG A Phase III Multicenter Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Moderate to…
M03-596 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 2 A Phase II Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
M02-529 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG A Phase II Multicenter Extension Study of the Safety and Efficacy of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque Psoriasis Gordon KB, Langley RG, Leonardi C, et al. Clinical Response to Adalimumab Treatment in Moderate to Severe Psoriasis Patients: Double-Blind, Randomized Clinical
M05-775 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
DE038 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti…
M06-806 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Disease
M03-600 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects with Rheumatoid Arth...
M10-240 AbbVie_IU_icons_outlined_v3 Juvenile Idiopathic Arthritis Phase 3 A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis
M02-404 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 2 A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
M05-770 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 Trial of Usability in Clinical Settings of the Humira Autoinjector vs Pre-filled Syringe (TOUCH)
M02-538 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 2 A Phase II Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
M10-239 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis Phase 3 A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
M04-684 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 Humira Efficacy Response Optimization Study in Subjects with Active Rheumatoid Arthritis (HERO)
DE018 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Multi-center Open-Label Continuation Study with Subcutaneous D2E7 for Patients with Rheumatoid Arthritis Who Completed a Precedi…
M02-537 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis Phase 2 A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients with Moderate to Severely Active Psoriatic Arthritis
M10-467 AbbVie_IU_icons_outlined_v3 Hidradenitis Suppurativa (HS) Phase 2 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis Suppurativa
M03-658 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Clinical Study with Adalimumab
M03-583 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG Multicenter Early Access Program (EAP) of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active R...
M06-859 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis
M10-060 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 A Multi-center Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination with Topical Treatment (Calcipotriol/Betamethasone) in Subjects with Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)
M04-724 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG Safety and Efficacy of Adalimumab in Patients with Active Psoriatic Arthritis (PsA) An Open-label, Multinational Study to Eva…
M10-444 AbbVie_IU_icons_outlined_v3 Juvenile Idiopathic Arthritis Phase 3 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
M02-518 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis CSR.ORG A Phase III Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Subjects…
M02-497 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-á Monoclonal Antibody Adalimuma…
M06-827 AbbVie_IU_icons_outlined_v3 Ulcerative Colitis Phase 3 A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis
M02-532 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 An Open-Label Study to Assess the Efficacy and Safety of the Fully Human Anti-TNF-alpha Monoclonal Antibody Adalimumab (D2E7) in patients with active Rheumatioid Arthritis who have failed Previous Treatment with Infliximab (Remicade)
M06-826 AbbVie_IU_icons_outlined_v3 Ulcerative Colitis Phase 3 A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis
M04-716 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
M05-760 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis Phase 3 Review of Safety and Efficacy With Adalimumab in Patients with Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors (RHAPSODY)
M03-583 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 Early Access Program (EAP) M03-583 Multicenter Early Access Program (EAP) of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis
P12-705 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 4 Reveal the Level of Anxiety in Patients with Crohn's Disease Receiving Adalimumab
M10-791 AbbVie_IU_icons_outlined_v3 Spondyloarthritis Phase 3 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis
M03-634 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis PMOS A Five-Year, Post-Marketing Observational Study to Follow-up Patients with Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed HUMIRA®
M02-529 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 2 A Phase 2 Multicenter Extension Study of the Safety and Efficacy of Adalimumab (D2E7) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
M02-403 AbbVie_IU_icons_outlined_v3 Crohn's Disease CSR.ORG A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Human Anti-TNF Monoclonal Antibody Adalimumab for the Induc…
M03-607 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis Phase 3 A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Ankylosing Spondylitis
M03-656 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Phase 3, Multicenter Study of the Efficacy and Safety of Long-term Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
M04-724 AbbVie_IU_icons_outlined_v3 Psoriatic Arthritis Phase 3 Safety and Efficacy of Adalimumab in Patients with Active Psoriatic Arthritis (PsA) An Open-label, Multinational Study to Eva…
M02-532 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG An Open-Label Study to Assess the Efficacy and Safety of the Fully Human Anti-TNF-alpha Monoclonal Antibody Adalimumab (D2E7) i…
M02-575 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose-Ranging Study of Subcutaneously Administered A…
M10-405 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 4 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
M04-684 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG HUMIRA Efficacy Response Optimization Study in Subjects with Active Rheumatoid Arthritis (HERO) Abbott Laboratories (Abbott)…
M04-690 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease
M10-447 AbbVie_IU_icons_outlined_v3 Ulcerative Colitis Phase 3 A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
M02-564 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis
M03-606 AbbVie_IU_icons_outlined_v3 Ankylosing Spondylitis Phase 3 A Phase III Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Ankylosing Spondylitis
M02-573 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with Methotrexate
M13-692 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 2 A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects Who Completed Preceding Study M13-390 With Adalimumab
M02-556 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis CSR.ORG A Randomized, Double-Blind, Placebo-controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcut…
M04-691 AbbVie_IU_icons_outlined_v3 Crohn's Disease CSR.ORG A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the...
M05-770 AbbVie_IU_icons_outlined_v3 Patient Preference Rheumatoid Arthritis Device CSR.ORG Trial of Usability in Clinical Settings of the HUMIRA Autoinjector vs. Pre-filled Syringe (TOUCH) Abbott Laboratories (Abbott…
M06-810 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 4 A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis (OPTIMA)
M02-575 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose-Ranging Study of Subcutaneously Administered Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
M04-729 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
M04-705 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
M02-556 AbbVie_IU_icons_outlined_v3 Rheumatoid Arthritis Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated with Methotrexate
M06-837 AbbVie_IU_icons_outlined_v3 Crohn's Disease Phase 3 A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
M10-238 AbbVie_IU_icons_outlined_v3 Psoriasis Phase 3 Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy
M02-528 AbbVie_IU_icons_outlined_v3 Psoriasis CSR.ORG A Phase 2, Multicenter Study of the Safety and Efficacy of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque Psor...
M06-808 AbbVie_IU_icons_outlined_v3 Crohn's Disease CSR.ORG A Multicenter, Open-Label Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease...
M12-555 AbbVie_IU_icons_outlined_v3 Hidradenitis Suppurativa (HS) Phase 3 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa – PIONEER (Open-Label Extension)